Golden window of intervention in PTSD: a synthesis of preclinical evidence

In the aftermath of trauma exposure, timing of clinical intervention is of crucial importance to prevent progression of disease symptoms. Present treatments sometimes fail to correct the whole range of symptoms, especially in cases of delayed interventions. Various pharmacological agents including steroids, benzodiazepines, selective serotonin reuptake inhibitors and anti-inflammatory drugs have been evaluated in rodent models for their timing-dependent efficacy. This is crucial considering the dynamic evolution of disease symptoms in trauma-aftermath. Thus, while some interventions that counter sympathetic hyperactivity (e.g., propranolol) and correct neuroendocrine function (e.g. glucocorticoids) are effective in the immediate and early phases, anti-inflammatory drugs could be better suited for delayed interventions occurring days to weeks later to combat long-term effects.

We synthesized existing evidence of such diverse pharmacological interventions at distinct timepoints across rat and mice acute stress paradigms.

We propose an updated concept of a 'sliding' golden window - where treatment strategies can be guided by the temporal evolution of symptoms post-trauma, to maximize drug efficacy. Such a dynamic, time-dependent pharmacological strategy could improve symptomatic outcomes of stress-disorders, with the preclinical body of evidence forming a strong foundational basis for future clinical validation across demographic factors and trauma etiologies.